🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This is great news and very important

I asked chatGPT to make my cartoon based on everything it learned from me based on my prior prompts 😂

Just out Blood Advances Zanubrutinib in patients who didn't tolerate ibrutinib or acalabrutinib. Updated results. pubmed.ncbi.nlm.nih.gov/40334067/ #CLL Jeff Sharman Fred Hutch Cancer Center

Save the date for our next Seattle Cellular Therapy Summit. Outstanding line of speakers and great topics. Krish Patel Binaytara Fred Hutch Cancer Center #SeattleCT25 urldefense.com/v3/__https://d…$

The SONIC trial is open to enrollment! In this investigator-initiated trial Fred Hutch Cancer Center , we study: "Rapid inpatient escalated ramp-up of Sonrotoclax in pts with #CLL or #MCL" cancer.gov/research/parti… Important to have different ramp-up options for bcl2 inhibitors.

We’re hiring! Fred Hutch/UW is recruiting a faculty member focused on T-cell lymphomas. Join a top-tier, collaborative lymphoma team with strong clinical + research support. Please share or reach out for details! apply.interfolio.com/168236 #HemOnc #Lymphoma #TCellLymphoma

Don't miss presentations from Fred Hutch Drs. Mazyar Shadman, MD MPH and Scott Ramsey this morning at #ASCO25. Learn more about their sessions: bit.ly/4kjp8yF

Mazyar Shadman, MD MPH on SEQUOIA Arm D. Zanu + ven looking good in treatment naive CLL/SLL with del17p and/or TP53 mutations #ASCO25 #CLLsn

Just out: @[email protected] SEQUOIA arm D results published simultaneously with the ASCO presentation. Great efficiency and safety of Zanu plus Ven in #CLL regardless of TP53 aberration. Fred Hutch Cancer Center UW Medicine Newsroom #ASCO25

.Mazyar Shadman, MD MPH of Fred Hutch presents combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) #CLL/SLL: results in SEQUOIA arm D at #ASCO25 brnw.ch/21wT3Ph

CONGRESS | #ASCO25 | PRESENTATION Mazyar Shadman, @MShadman, @FredHutch, presents findings from results in SEQUOIA arm D with zanu + ven in TN CLL/SLL with or without del(17p) and/or TP53mut. - Promising efficacy and tolerability, regardless of the mutation status. Follow our

These promising results set the stage for adding anti-CD20 antibody therapy to this regimen. Journal of Clinical Oncology

Congrats to our Fred Hutch researchers recognized with the prestigious 2025 ASCO Young Investigator Award! They each received a $50,000 grant from the Conquer Cancer, the ASCO Foundation to support their innovative research. #ASCO25 bit.ly/3FFv8CO

Incredibly thankful for the support from Conquer Cancer, the ASCO Foundation and the fantastic mentorship from Mazyar Shadman, MD MPH and Jordan Gauthier! Looking forward to better understanding the impact of BTK inhibitors on CAR T-cell biology!

Presented at #ASCO25 were results from arm D of the SEQUOIA trial, led by Mazyar Shadman, MD MPH of Fred Hutch Cancer Center, evaluating zanubrutinib plus venetoclax in #chroniclymphocyticleukemia, #smalllymphocyticlymphoma. #CLL, #SLL, #Heme buff.ly/R1HrU4u

Furthering our work for best strategy in established chemosensitive MYC+ LBCL #lymsm CART of autoHCT? #bmtsm Fateeha Furqan et al. onlinelibrary.wiley.com/doi/full/10.10…

Mazyar Shadman, MD MPH at @FredHutch was honored with the #Binaytara Distinguished Faculty of the Year Award for improving #CancerCare access and education at #SCHD25. 📖Discover how Dr. Shadman enhances CAR-T access: buff.ly/sZuz5gP 🎯Join our CME/ACPE-accredited events:

CONGRESS | #18ICML | POSTER Mazyar Shadman Mazyar Shadman, MD MPH, Fred Hutch Cancer Center presents Arm D results from the phase III SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve #CLL/SLL (N = 114). At 24 months, PFS was 92%, and PB uMRD rate was 59%, with consistent outcomes in